What happens years after CAR-T therapy? a study aims to find out

NCT ID NCT06116110

Recruiting now Knowledge-focused Sponsor: Miltenyi Biomedicine GmbH Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This study follows people who previously received zamtocabtagene autoleucel, a CAR-T cell therapy for certain types of lymphoma. The goal is to monitor long-term health outcomes, including any new cancers, neurological issues, or autoimmune problems. By tracking participants over time, researchers hope to better understand the lasting effects and safety of this treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Long-term follow-up observation (no new intervention)
What this could lead to: If successful, this study could provide crucial safety data on the long-term effects of zamtocabtagene autoleucel, helping to ensure its safe use in future patients.
What could go wrong: This is an observational study, so it cannot prove the treatment works. It only monitors outcomes, and results may take years to accumulate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma high grade B-cell lymphoma non-Hodgkin lymphoma primary central nervous system lymphoma primary mediastinal large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CENTRAL NERVOUS SYSTEM LYMPHOMA HIGH-GRADE B-CELL LYMPHOMA NON-HODGKIN LYMPHOMA PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBCL) REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) RELAPSED DIFFUSE LARGE B CELL LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Banner MD Anderson Cancer Center
RECRUITING

Gilbert, Arizona, 85234, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Duke University Medical Center - Division of Hematologic Malignancies
RECRUITING

Durham, North Carolina, 27705, United States
Froedtert Hospital and the Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Oregon Health and Science University Knight Cancer Institute
RECRUITING

Portland, Oregon, 97239, United States
Robert H Lurie Cancer Center
RECRUITING

Chicago, Illinois, 60611, United States
Stanford University
RECRUITING

Stanford, California, 94305, United States
UT Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States
University of Kansas Cancer Center
RECRUITING

Westwood, Kansas, 66205, United States
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
NOT_YET_RECRUITING

Baltimore, Maryland, 21201, United States
Yale University
RECRUITING

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.